Omega Fund Management’s Cymabay Therapeutics CBAY Stock Holding History

Omega Fund Management’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-551,477	Closed	-$7.32M	–	16
2019 Q1	$7.32M	Hold	551,477	–	–	2.35%	6
2018 Q4	$4.34M	Hold	551,477	–	–	3.22%	7
2018 Q3	$6.11M	Hold	551,477	–	–	2.89%	9
2018 Q2	$7.4M	Hold	551,477	–	–	5.46%	8
2018 Q1	$7.16M	Hold	551,477	–	–	7.04%	5
2017 Q4	$5.07M	Hold	551,477	–	–	3.67%	8
2017 Q3	$4.45M	Buy	551,477 +250,000	+83%	+$1.69M	2.51%	7
2017 Q2	$1.74M	Hold	301,477	–	–	1.08%	9
2017 Q1	$1.3M	Hold	301,477	–	–	0.84%	10
2016 Q4	$522K	Hold	301,477	–	–	0.42%	11
2016 Q3	$585K	Sell	301,477 -304,623	-50%	-$606K	0.45%	11
2016 Q2	$1.05M	Hold	606,100	–	–	0.78%	10
2016 Q1	$818K	Sell	606,100 -43,900	-7%	-$54.4K	0.57%	11
2015 Q4	$1.1M	Hold	650,000	–	–	0.61%	10
2015 Q3	$1.26M	Buy	+650,000	New	+$1.77M	0.71%	10

Other funds holding CBAY

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Omega Fund Management's CBAY Position: Q2 2019 in Review

Omega Fund Management sold out of Cymabay Therapeutics (CBAY) in Q2 2019, closing a stake of 551,477 shares — an estimated $7.32M sold.

Omega Fund Management first reported a position in CBAY in Q3 2015 and held it in 15 quarters. The position peaked at $7.4M in Q2 2018. 133 funds tracked by Wall St. Rank hold CBAY as of Q2 2019.

Omega Fund Management reported no remaining Cymabay Therapeutics position as of Q2 2019 after selling out during the quarter.
Omega Fund Management sold 551,477 Cymabay Therapeutics shares in Q2 2019, an estimated $7.32M.
Omega Fund Management first reported a position in Cymabay Therapeutics in Q3 2015 and held it in 15 quarters.
Omega Fund Management's Cymabay Therapeutics position peaked at $7.4M in Q2 2018.
133 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2019.

Based on Omega Fund Management's 13F filing for Q2 2019, filed 13 Aug 2019.